Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer.
Pellicane JV, Beitsch PD, Rock DT, Budway RJ, Dul CL, Kelemen PR, Ashikari AY, Baron PL, Weinstein PD, Mislowsky A, Lee LA, Beatty J, Murray MK, Dupree BB, Finn C, Corcoran K, Wang S, Menicucci AR, Yoder EB, Blumencranz LE, Dauer P, Audeh W, Whitworth PW; NBRST Investigators Group. Pellicane JV, et al. Among authors: blumencranz le. Surg Oncol. 2022 Dec;45:101885. doi: 10.1016/j.suronc.2022.101885. Epub 2022 Nov 22. Surg Oncol. 2022. PMID: 36436423 Free article.
Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.
Tsai M, Lo S, Audeh W, Qamar R, Budway R, Levine E, Whitworth P, Mavromatis B, Zon R, Oldham D, Untch S, Treece T, Blumencranz L, Soliman H. Tsai M, et al. JAMA Oncol. 2018 Jan 11;4(1):e173470. doi: 10.1001/jamaoncol.2017.3470. Epub 2018 Jan 11. JAMA Oncol. 2018. PMID: 29075751 Free PMC article.
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer.
Whitworth P, Beitsch PD, Pellicane JV, Baron PL, Lee LA, Dul CL, Nash CH 3rd, Murray MK, Richards PD, Gittleman M, Budway R, Rahman RL, Kelemen P, Dooley WC, Rock DT, Cowan K, Lesnikoski BA, Barone JL, Ashikari AY, Dupree B, Wang S, Menicucci AR, Yoder EB, Finn C, Corcoran K, Blumencranz LE, Audeh W; NBRST Investigators Group. Whitworth P, et al. Among authors: blumencranz le. Ann Surg Oncol. 2022 Apr 4;29(7):4141-52. doi: 10.1245/s10434-022-11666-2. Online ahead of print. Ann Surg Oncol. 2022. PMID: 35378634 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 35438465
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.
Whitworth PW, Beitsch PD, Pellicane JV, Baron PL, Lee LA, Dul CL, Murray MK, Gittleman MA, Budway RJ, Rahman RL, Kelemen PR, Dooley WC, Rock DT, Cowan KH, Lesnikoski BA, Barone JL, Ashikari AY, Dupree BB, Wang S, Menicucci AR, Yoder EB, Finn C, Corcoran K, Blumencranz LE, Audeh W; NBRST Investigators Group. Whitworth PW, et al. Among authors: blumencranz le. JCO Precis Oncol. 2022 Apr;6(1):e2100463. doi: 10.1200/PO.21.00463. JCO Precis Oncol. 2022. PMID: 35476550 Free PMC article.
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy.
Whitworth PW, Beitsch PD, Murray MK, Richards PD, Mislowsky A, Dul CL, Pellicane JV, Baron PL, Rahman RL, Lee LA, Dupree BB, Kelemen PR, Ashikari AY, Budway RJ, Lopez-Penalver C, Dooley W, Wang S, Dauer P, Menicucci AR, Yoder EB, Finn C, Blumencranz LE, Audeh W. Whitworth PW, et al. Among authors: blumencranz le. JCO Precis Oncol. 2022 Sep;6:e2200197. doi: 10.1200/PO.22.00197. JCO Precis Oncol. 2022. PMID: 36108259 Free PMC article.
The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy.
Blumencranz P, Habibi M, Shivers S, Acs G, Blumencranz LE, Yoder EB, van der Baan B, Menicucci AR, Dauer P, Audeh W, Cox CE. Blumencranz P, et al. Among authors: blumencranz le. Ann Surg Oncol. 2023 Dec;30(13):8353-8361. doi: 10.1245/s10434-023-14027-9. Epub 2023 Sep 1. Ann Surg Oncol. 2023. PMID: 37658272 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 37787953
Molecular analysis of breast sentinel lymph nodes.
Blumencranz PW, Pieretti M, Allen KG, Blumencranz LE. Blumencranz PW, et al. Among authors: blumencranz le. Surg Oncol Clin N Am. 2011 Jul;20(3):467-85, viii. doi: 10.1016/j.soc.2011.01.002. Surg Oncol Clin N Am. 2011. PMID: 21640916 Review.